The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo

Cancer Genetics and Cytogenetics

Volumn 130, Issue 2, 2001, Pages 93-104

  Andreasson, Patrik ^a,b   Schwaller, Juerg ^a   Anastasiadou, Ema ^a   Aster, Jon ^a   Gilliland, D Gary ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 3; INTERLEUKIN 7; VIRUS VECTOR;

ANIMAL CELL; BREEDING; CELL LINE; CELL TRANSFORMATION; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; GENETIC VARIABILITY; HEMATOLOGIC DISEASE; HEMATOPOIESIS; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SPLICING; TRANSGENIC ANIMAL; WESTERN BLOTTING;

EID: 0035886409     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(01)00518-0     Document Type: Article

References (90)

1. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials
2. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
3. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
4. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pedriatic ALL and defines a subgroup of patients with an excellent prognosis
5. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
6. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion
7. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
8. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms
9. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRb oncoprotein
10. The TEL gene products: Nuclear phosphoproteins with DNA binding properties
11. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
12. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
13. The novel activation of ABL by fusion to an ets-related gene, TEL
14. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia
15. The TEL/platelet-derived growth factor b receptor (PDGFbR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFbR kinase-dependent signaling pathways
16. Evidence for a role of NF-kB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor b fusion protein
17. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
18. Haemopoietic transformation by the TEL/ABL oncogene
19. TEL/PDGFbR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
20. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO
21. ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRa enhancer function
22. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation
23. Multiple functional domains of AML1: PU.1 and C/EBPa synergize with different regions of AML1
24. ETS-core binding factor: A common composite motif in antigen receptor gene enhancers
25. The AML1/ETO fusion protein activates transcription of BCL-2
26. A new transcription factor family associated with human leukemias
27. The runt domain identifies a new family of heteromeric transcriptional regulators
28. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions
29. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization
30. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia
31. A novel transcript encoding an N-terminally truncated AML1/PEBP2aB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells
32. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms
33. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B
34. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation
35. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias
36. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-a, inhibits C/EBP-a-dependent transcription, and blocks granulocytic differentiation
37. AML1a but not AML1b inhibits erythroid differentiation induced by sodium butyrate and enhances the megakaryocytic differentiation of K562 leukemia cells
38. Acute myeloid leukemia with inv(16) produces a chimeric transcription factor with a myosin heavy chain tail
39. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11
40. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis
41. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
42. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor b
43. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis
44. The CBFb subunit is essential for CBFa2 (AML1) function in vivo
45. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene
46. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription
47. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL
48. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow
49. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia
50. The 12;21 translocation involving TEL and deletion of the other TEL allele: Two frequently associated alterations found in childhood acute lymphoblastic leukemia
51. Analysis of TEL proteins in human leukemias
52. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia
53. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation
54. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22)
55. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells
56. Acute promyelocytic leukemia cases with nonreciprocal PML/RARa or RARa/PML fusion genes
57. Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7- dependent cell line
58. Versatile retroviral vectors for potential use in gene therapy
59. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL
60. Kat: A high-efficiency retroviral transduction system for primary human T lymphocytes
61. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: Implications for t(8;21) leukemogenesis and monitoring residual disease
62. bcr/abl protein
63. bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line
64. AML1A and AML1B can transactivate the human IL-3 promoter
65. Expression of the immunoglobulin C mu gene in mouse T and B lymphoid and myeloid cell lines
66. Core-binding factor: A central player in hematopoiesis and leukemia
67. Combinatorial regulation of transcription II: The immunoglobulin m heavy chain gene
68. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
69. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice
70. Acute leukaemia in bcr/abl transgenic mice
71. Introduction of a mu immunoglobulin gene into the mouse germ line: Specific expression in lymphoid cells and synthesis of functional antibody
72. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes
73. Distinct interactions of PML-RARa and PLZF-RARa with co-repressors determine differential responses to RA in APL
74. E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice
75. B-cell development: A comparison between mouse and man
76. The distribution of CD10 (NEP 24.11, CALLA) in humans and mice is similar in non-lymphoid organs but differs within the hematopoietic system: Absence on murine T and B lymphoid progenitors
77. Translocations, master genes, and differences between the origins of acute and chronic leukemias
78. The PEBP2bMYH11 fusion created by inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia
79. The fusion gene Cbfb-MYH11 block myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia
80. Expression of AML1-ETO immortalizes myeloid progenitors and cooperates with secondary mutations to induce granulocytic sarcoma/acute myeloid leukemia
81. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia
82. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero
83. TEL/AML1 transcript and p16 gene deletion in a patient with childhood acute lymphoblastic leukaemia
84. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines
85. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia
86. Kip1 protein: Prognostic implications in primary breast cancer
87. Kip1 is haplo-insufficient for tumour suppression
88. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
89. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
90. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients